Investigation of Tricida, Inc.

Tricida, Inc. (TCDA) Misled Shareholders About the Viability of its Clinical Trial and Efficacy of its Lead Drug Candidate  

Tricida conducted a single Phase 3 study for veverimer and sought approval under the FDA’s Accelerated Drug Application (“ADA”) program.  Based on the strength of these trial results, Tricida went public on June 28, 2018.  The offering registration statement and its prospectus misrepresented material facts.  Specifically, the prospectus informed investors that Tricida’s “double blind, randomized, placebo-controlled” trial was conducted “at 47 sites in the United States and Europe,” touted the success of the trial, and stated that “based on feedback from the FDA … [the] trial[] will provide sufficient evidence of clinical safety and efficacy to support the submission and review of an NDA for TRC101 pursuant to the [ADA].”  For years, Tricida’s executives touted the success of the trial and hid the truth from investors.

On February 25, 2021, Tricida finally informed investors that the FDA had rejected the New Drug Application for veverimer, and the FDA’s Office of New Drugs denied Tricida’s appeal.  Specifically, the FDA concluded: (1) the “extent of serum bicarbonate increase observed in the [] trial is not reasonably likely to provide a discernible reduction in CKD progression; (2) “the confirmatory trial, VALOR-CKD, is underpowered;” (3) the trial results were “strongly influenced by a single site;” and (4) “the majority of sites for the [] trial” were in Eastern Europe, “where differences in patient management … might affect the treatment response to veverimer” “raising a concern of the applicability to a U.S. patient population.”  The stock fell on this news, wiping out $93 million in market capitalization.


Tricida, Inc. (TCDA) shareholders have options.  

All representation is on a contingency fee basis.  Shareholders pay no fees or expenses

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

Name*
Ticker + Amount
This field is for validation purposes and should be left unchanged.